Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CS-2034 mRNA Vaccine Booster in Adults
NCT05568693Unknown
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Vaccine mRNA, Lipid-based Nanoparticles, mRNA Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of CS-2034 in coronavirus disease 2019 (COVID-19). Primary endpoints: Incidence of adverse reactions (AR) at 28 days and Incidence of Serious Adverse Event (SAE) and Adverse Event of Special Interest (AESI) at 6 months. Status: unknown.
02
Drugs
CS-2034
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05568693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568693.